Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NUVECTIS PHARMA INC (NVCT) Stock Price & Overview
NASDAQ:NVCT • US67080T1088
Current stock price
8.56 USD
+0.06 (+0.71%)
At close:
8.56 USD
0 (0%)
After Hours:
The current stock price of NVCT is 8.56 USD. Today NVCT is up by 0.71%. In the past month the price increased by 12.63%. In the past year, price decreased by -7.46%.
NVCT Key Statistics
52-Week Range5.55 - 11.15
Current NVCT stock price positioned within its 52-week range.
1-Month Range7.44 - 9.2099
Current NVCT stock price positioned within its 1-month range.
- Market Cap
- 226.754M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.21
- Dividend Yield
- N/A
NVCT Stock Performance
Today
+0.71%
1 Week
-2.62%
1 Month
+12.63%
3 Months
+5.55%
Longer-term
6 Months +27.57%
1 Year -7.46%
2 Years +40.79%
3 Years -42.16%
5 Years N/A
10 Years N/A
NVCT Stock Chart
NVCT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NVCT. When comparing the yearly performance of all stocks, NVCT is a bad performer in the overall market: 69.31% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
NVCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCT. NVCT has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVCT Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateFeb 11, 2026
PeriodQ4 / 2025
EPS Reported-$0.31
Revenue Reported
EPS Surprise -2.16%
Revenue Surprise %
NVCT Forecast & Estimates
12 analysts have analysed NVCT and the average price target is 18.87 USD. This implies a price increase of 120.44% is expected in the next year compared to the current price of 8.56.
Analysts
Analysts83.33
Price Target18.87 (120.44%)
EPS Next Y-5.16%
Revenue Next YearN/A
NVCT Index Membership
NVCT is currently included in the following stock indexes tracked on ChartMill.
NVCT Financial Highlights
Over the last trailing twelve months NVCT reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS decreased by -9.01% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-28.87M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.05% | ||
| ROE | -156.8% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%13.89%
Sales Q2Q%N/A
EPS 1Y (TTM)-9.01%
Revenue 1Y (TTM)N/A
NVCT Ownership
Ownership
Inst Owners17.19%
Shares26.49M
Float15.47M
Ins Owners41.59%
Short Float %9.96%
Short Ratio28.52
NVCT Industry Overview
NVCT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
NVCT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVCT
Company Profile
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Company Info
IPO: 2022-02-04
NUVECTIS PHARMA INC
1 Bridge Plaza, 2nd Floor
Fort Lee NEW JERSEY US
Employees: 13
Phone: 13608377232
NUVECTIS PHARMA INC / NVCT FAQ
What does NUVECTIS PHARMA INC do?
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Can you provide the latest stock price for NUVECTIS PHARMA INC?
The current stock price of NVCT is 8.56 USD. The price increased by 0.71% in the last trading session.
Does NVCT stock pay dividends?
NVCT does not pay a dividend.
What is the ChartMill rating of NUVECTIS PHARMA INC stock?
NVCT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of NVCT stock?
NUVECTIS PHARMA INC (NVCT) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of NUVECTIS PHARMA INC (NVCT) based on its PE ratio?
NUVECTIS PHARMA INC (NVCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).